TPMT and acute lymphoblastic leukemia: Finally, our results support the hypothesis that transcriptional genetic modifiers, such as the VNTR region in the TPMT promoter, may be used as a pharmacogenetic biomarker and could contribute to the design of personalized ALL childhood therapy.